Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

December 17, 2019

Primary Completion Date

January 31, 2041

Study Completion Date

January 31, 2041

Conditions
BreastBreast Cancer
Interventions
DRUG

pegfilgrastim

It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.

Trial Locations (2)

27157

RECRUITING

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

28204

RECRUITING

Levine Cancer Institute, Charlotte

All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER